Untitled Document
 
Untitled Document
 
Untitled Document
 
 
 
 
 
 
¬¬¬ã¬Ñ¬Ý¬Ü¬à¬â¬Ú ¬Ü¬å¬á¬Ú¬Ý¬Ú ¬Ó ¬ï¬ä¬à¬Û ¬Ñ¬á¬ä¬Ö¬Ü¬Ö ¬ã ¬Ò¬í¬ã¬ä¬â¬à¬Û ¬Õ¬à¬ã¬ä¬Ñ¬Ó¬Ü¬à¬Û
ÀÛ¼ºÀÚ Simanepay
³»¿ë ¬¹¬ä¬à¬Ò¬í ¬Ó¬í¬Ý¬Ö¬é¬Ú¬ä¬î ¬â¬Ñ¬Ü, ¬ä¬â¬Ö¬Ò¬å¬Ö¬ä¬ã¬ñ ¬Õ¬à¬â¬à¬Ô¬à¬ã¬ä¬à¬ñ¬ë¬Ö¬Ö ¬Ú ¬ï¬æ¬æ¬Ö¬Ü¬ä¬Ú¬Ó¬ß¬à¬Ö
¬Ý¬Ö¬é¬Ö¬ß¬Ú¬Ö.
¬®¬Ö¬Õ¬Ú¬Ü¬Ñ¬Þ¬Ö¬ß¬ä ¬¬¬ã¬Ñ¬Ý¬Ü¬à¬â¬Ú (Crizotinib) - Xalkori (¬¬¬â¬Ú¬Ù¬à¬ä¬Ú¬ß¬Ú¬Ò)
¬á¬â¬Ö¬Õ¬ß¬Ñ¬Ù¬ß¬Ñ¬é¬Ö¬ß ¬Õ¬Ý¬ñ ¬ä¬Ö¬â¬Ñ¬á¬Ú¬Ú ¬ß¬Ö¬Þ¬Ö¬Ý¬Ü¬à¬Ü¬Ý¬Ö¬ä¬à¬é¬ß¬à¬Ô¬à ¬â¬Ñ¬Ü¬Ñ ¬Ý¬×¬Ô¬Ü¬Ú¬ç. ¬¯¬à¬Ó¬Ö¬Û¬ê¬Ö¬Ö ¬ã¬â¬Ö¬Õ¬ã¬ä¬Ó¬à ¬å¬ã¬á¬Ö¬Ý¬à ¬à¬ä¬Ý¬Ú¬é¬ß¬à ¬Ù¬Ñ¬â¬Ö¬Ü¬à¬Þ¬Ö¬ß¬Õ¬à¬Ó¬Ñ¬ä¬î ¬ã¬Ö¬Ò¬ñ ¬Ó ¬ä¬Ö¬â¬Ñ¬á¬Ú¬Ú ¬ã¬Ö¬â¬î¬×¬Ù¬ß¬à¬Ô¬à ¬Ù¬Ñ¬Ò¬à¬Ý¬Ö¬Ó¬Ñ¬ß¬Ú¬ñ.

¬³¬à¬ã¬ä¬Ñ¬Ó ¬Ú ¬ã¬Ó¬à¬Û¬ã¬ä¬Ó¬Ñ
¬£ ¬ï¬æ¬æ¬Ö¬Ü¬ä¬Ú¬Ó¬ß¬í¬Û ¬á¬â¬Ö¬á¬Ñ¬â¬Ñ¬ä ¬á¬à¬ã¬Ý¬Ö¬Õ¬ß¬Ö¬Ô¬à ¬á¬à¬Ü¬à¬Ý¬Ö¬ß¬Ú¬ñ ¬Ó¬ç¬à¬Õ¬Ú¬ä ¬Ñ¬Ü¬ä¬Ú¬Ó¬ß¬à¬Ö
¬Ý¬Ö¬Ü¬Ñ¬â¬ã¬ä¬Ó¬Ö¬ß¬ß¬à¬Ö ¬Ó¬Ö¬ë¬Ö¬ã¬ä¬Ó¬à ¬Ü¬â¬Ú¬Ù¬à¬ä¬Ú¬ß¬Ú¬Ò, ¬Ü¬à¬ä¬à¬â¬à¬Ö ¬ñ¬Ó¬Ý¬ñ¬Ö¬ä¬ã¬ñ
¬ã¬Ö¬Ý¬Ö¬Ü¬ä¬Ú¬Ó¬ß¬í¬Þ ¬Ú¬ß¬Ô¬Ú¬Ò¬Ú¬ä¬à¬â¬à¬Þ ¬ä¬Ú¬â¬à¬Ù¬Ú¬ß¬Ü¬Ú¬ß¬Ñ¬Ù¬í ¬Ú ¬Ü¬Ú¬ß¬Ñ¬Ù¬í ¬Ñ¬ß¬Ñ¬á¬Ý¬Ñ¬ã¬ä¬Ú¬é¬Ö¬ã¬Ü¬à¬Û
¬Ý¬Ú¬Þ¬æ¬à¬Þ¬í.
¬´¬Ñ¬Ü¬Ø¬Ö ¬Ó ¬á¬â¬Ö¬á¬Ñ¬â¬Ñ¬ä ¬Ó¬Ü¬Ý¬ð¬é¬Ö¬ß¬í ¬Õ¬à¬á¬à¬Ý¬ß¬Ú¬ä¬Ö¬Ý¬î¬ß¬í¬Ö ¬Ó¬Ö¬ë¬Ö¬ã¬ä¬Ó¬Ñ,
¬Ü¬à¬ä¬à¬â¬í¬Ö ¬ã¬á¬à¬ã¬à¬Ò¬ã¬ä¬Ó¬å¬ð¬ä ¬Ý¬å¬é¬ê¬Ö¬Û ¬Ñ¬Ò¬ã¬à¬â¬Ò¬è¬Ú¬Ú ¬Ý¬Ö¬Ü¬Ñ¬â¬ã¬ä¬Ó¬Ö¬ß¬ß¬à¬Ô¬à
¬Ó¬Ö¬ë¬Ö¬ã¬ä¬Ó¬Ñ.
¬­¬Ö¬Ü¬Ñ¬â¬ã¬ä¬Ó¬à ¬á¬à¬ã¬Ý¬Ö¬Õ¬ß¬Ö¬Ô¬à ¬á¬à¬Ü¬à¬Ý¬Ö¬ß¬Ú¬ñ ¬á¬â¬Ö¬Ü¬â¬Ñ¬ë¬Ñ¬Ö¬ä ¬Õ¬Ñ¬Ý¬î¬ß¬Ö¬Û¬ê¬Ö¬Ö ¬â¬Ñ¬Ù¬Ó¬Ú¬ä¬Ú¬Ö
¬Ù¬Ý¬à¬Ü¬Ñ¬é¬Ö¬ã¬ä¬Ó¬Ö¬ß¬ß¬à¬Û ¬à¬á¬å¬ç¬à¬Ý¬Ú ¬Ú ¬å¬Ò¬Ú¬Ó¬Ñ¬Ö¬ä ¬â¬Ñ¬Ü¬à¬Ó¬í¬Ö ¬Ü¬Ý¬Ö¬ä¬Ü¬Ú.
¬£ ¬â¬Ö¬Ù¬å¬Ý¬î¬ä¬Ñ¬ä¬Ö ¬Ó¬à¬Ù¬Õ¬Ö¬Û¬ã¬ä¬Ó¬Ú¬ñ ¬ã¬â¬Ö¬Õ¬ã¬ä¬Ó¬Ñ ¬á¬â¬à¬Ú¬ã¬ç¬à¬Õ¬Ú¬ä ¬Ú¬ß¬Õ¬å¬è¬Ú¬â¬à¬Ó¬Ñ¬ß¬Ú¬Ö
¬Ü¬â¬Ú¬Ù¬à¬ä¬Ú¬ß¬Ú¬Ò¬à¬Þ ¬à¬á¬å¬ç¬à¬Ý¬Ö¬Ó¬í¬ç ¬Ü¬Ý¬Ö¬ä¬à¬é¬ß¬í¬ç ¬ã¬ä¬â¬å¬Ü¬ä¬å¬â.
¬±¬â¬Ö¬á¬Ñ¬â¬Ñ¬ä ¬¬¬ã¬Ñ¬Ý¬Ü¬à¬â¬Ú ¬Þ¬à¬ë¬ß¬à¬Ö ¬á¬â¬à¬ä¬Ú¬Ó¬à¬à¬á¬å¬ç¬à¬Ý¬Ö¬Ó¬à¬Ö ¬ã¬â¬Ö¬Õ¬ã¬ä¬Ó¬à,
¬Ü¬à¬ä¬à¬â¬à¬Ö ¬é¬Ñ¬ã¬ä¬à ¬ß¬Ñ¬Ù¬ß¬Ñ¬é¬Ñ¬Ö¬ä¬ã¬ñ ¬Ó¬â¬Ñ¬é¬Ñ¬Þ¬Ú, ¬Ö¬ã¬Ý¬Ú ¬á¬â¬Ö¬Õ¬í¬Õ¬å¬ë¬Ö¬Ö ¬Ý¬Ö¬é¬Ö¬ß¬Ú¬Ö
¬â¬Ñ¬Ü¬Ñ ¬Ý¬×¬Ô¬Ü¬Ú¬ç ¬ß¬Ö ¬á¬â¬Ú¬ß¬Ö¬ã¬Ý¬à ¬á¬à¬Ý¬à¬Ø¬Ú¬ä¬Ö¬Ý¬î¬ß¬à¬Ô¬à ¬â¬Ö¬Ù¬å¬Ý¬î¬ä¬Ñ¬ä¬Ñ.
¬±¬â¬à¬ä¬Ú¬Ó¬à¬à¬á¬å¬ç¬à¬Ý¬Ö¬Ó¬à¬Ö ¬Ó¬à¬Ù¬Õ¬Ö¬Û¬ã¬ä¬Ó¬Ú¬Ö ¬ã¬â¬Ö¬Õ¬ã¬ä¬Ó¬Ñ ¬ñ¬Ó¬Ý¬ñ¬Ö¬ä¬ã¬ñ ¬Õ¬à¬Ù¬à¬Ù¬Ñ¬Ó¬Ú¬ã¬Ú¬Þ¬í¬Þ.
¬¹¬ä¬à¬Ò¬í ¬Þ¬Ö¬Õ¬Ú¬Ü¬Ñ¬Þ¬Ö¬ß¬ä
¬¬¬ã¬Ñ¬Ý¬Ü¬à¬â¬Ú (Crizotinib) - Xalkori (¬¬¬â¬Ú¬Ù¬à¬ä¬Ú¬ß¬Ú¬Ò) ¬Ü¬å¬á¬Ú¬ä¬î ¬á¬à ¬ã¬ß¬Ú¬Ø¬Ö¬ß¬ß¬à¬Û ¬è¬Ö¬ß¬Ö, ¬à¬Ò¬â¬Ñ¬ë¬Ñ¬Û¬ä¬Ö¬ã¬î ¬Ó ¬ß¬Ñ¬ê¬å ¬Ú¬ß¬ä¬Ö¬â¬ß¬Ö¬ä ¬Ñ¬á¬ä¬Ö¬Ü¬å.

¬±¬à¬Ü¬Ñ¬Ù¬Ñ¬ß¬Ú¬ñ
ALK-¬á¬à¬Ù¬Ú¬ä¬Ú¬Ó¬ß¬í¬Û ¬ß¬Ö¬Þ¬Ö¬Ý¬Ü¬à¬Ü¬Ý¬Ö¬ä¬à¬é¬ß¬í¬Û ¬â¬Ñ¬Ü; ROS-1-¬á¬à¬Ù¬Ú¬ä¬Ú¬Ó¬ß¬í¬Û ¬â¬Ñ¬Ü ¬Ý¬×¬Ô¬Ü¬à¬Ô¬à.

¬±¬â¬à¬ä¬Ú¬Ó¬à¬á¬à¬Ü¬Ñ¬Ù¬Ñ¬ß¬Ú¬ñ
¬Ô¬Ú¬á¬Ö¬â¬é¬å¬Ó¬ã¬ä¬Ó¬Ú¬ä¬Ö¬Ý¬î¬ß¬à¬ã¬ä¬î ¬Ü ¬ã¬à¬ã¬ä¬Ñ¬Ó¬å ¬ã¬â¬Ö¬Õ¬ã¬ä¬Ó¬Ñ; ¬Ò¬Ö¬â¬Ö¬Þ¬Ö¬ß¬ß¬à¬ã¬ä¬î; ¬Ý¬Ñ¬Ü¬ä¬Ñ¬è¬Ú¬ñ; ¬Õ¬Ö¬ä¬ã¬Ü¬Ú¬Û ¬Ó¬à¬Ù¬â¬Ñ¬ã¬ä;
¬á¬Ö¬é¬×¬ß¬à¬é¬ß¬Ñ¬ñ ¬ß¬Ö¬Õ¬à¬ã¬ä¬Ñ¬ä¬à¬é¬ß¬à¬ã¬ä¬î; ¬ã¬à¬Ó¬Þ¬Ö¬ã¬ä¬ß¬í¬Û ¬á¬â¬Ú¬×¬Þ ¬ã ¬Ú¬ß¬Ô¬Ú¬Ò¬Ú¬ä¬à¬â¬Ñ¬Þ¬Ú CYP3A.

¬³¬á¬à¬ã¬à¬Ò ¬á¬â¬Ú¬Þ¬Ö¬ß¬Ö¬ß¬Ú¬ñ
¬±¬â¬Ú¬×¬Þ ¬Õ¬Ñ¬ß¬ß¬à¬Ô¬à ¬Ý¬Ö¬Ü¬Ñ¬â¬ã¬ä¬Ó¬Ñ ¬ß¬Ö ¬Ù¬Ñ¬Ó¬Ú¬ã¬Ú¬ä ¬à¬ä ¬å¬á¬à¬ä¬â¬Ö¬Ò¬Ý¬Ö¬ß¬Ú¬ñ ¬á¬Ú¬ë¬Ú. ¬¬¬Ñ¬á¬ã¬å¬Ý¬Ñ ¬á¬â¬à¬Ô¬Ý¬Ñ¬ä¬í¬Ó¬Ñ¬Ö¬ä¬ã¬ñ,
¬ß¬Ö ¬â¬Ñ¬Ù¬Ø¬×¬Ó¬í¬Ó¬Ñ¬ñ¬ã¬î. ¬´¬â¬Ö¬Ò¬å¬Ö¬ä¬ã¬ñ ¬ß¬Ö¬á¬â¬Ö¬Þ¬Ö¬ß¬ß¬à ¬Ù¬Ñ¬á¬Ú¬ä¬î ¬Þ¬Ö¬Õ¬Ú¬Ü¬Ñ¬Þ¬Ö¬ß¬ä ¬é¬Ú¬ã¬ä¬à¬Û ¬Ó¬à¬Õ¬à¬Û.
¬®¬Ö¬Õ¬Ú¬Ü¬Ú ¬â¬Ö¬Ü¬à¬Þ¬Ö¬ß¬Õ¬å¬ð¬ä ¬Õ¬à¬Ù¬å ¬á¬â¬Ö¬á¬Ñ¬â¬Ñ¬ä¬Ñ - 250 ¬Þ¬Ô (2 ¬â¬Ñ¬Ù¬Ñ ¬Ó ¬ã¬å¬ä¬Ü¬Ú).
¬¯¬Ö ¬ã¬Ý¬Ö¬Õ¬å¬Ö¬ä ¬å¬Õ¬Ó¬Ñ¬Ú¬Ó¬Ñ¬ä¬î ¬Ý¬Ö¬Ü¬Ñ¬â¬ã¬ä¬Ó¬Ö¬ß¬ß¬å¬ð ¬Õ¬à¬Ù¬Ú¬â¬à¬Ó¬Ü¬å ¬á¬â¬Ú ¬á¬â¬à¬á¬å¬ã¬Ü¬Ö ¬å¬á¬à¬ä¬â¬Ö¬Ò¬Ý¬Ö¬ß¬Ú¬ñ ¬ã¬â¬Ö¬Õ¬ã¬ä¬Ó¬Ñ.
¬¬¬à¬â¬â¬Ö¬Ü¬è¬Ú¬ñ ¬Õ¬à¬Ù¬í ¬Ù¬Ñ¬Ó¬Ú¬ã¬Ú¬ä ¬à¬ä ¬Ó¬í¬â¬Ñ¬Ø¬Ö¬ß¬ß¬à¬ã¬ä¬Ú CTCAE.
¬±¬â¬Ú ¬Ó¬í¬â¬Ñ¬Ø¬Ö¬ß¬ß¬í¬ç ¬á¬à¬Ò¬à¬é¬ß¬í¬ç ¬ï¬æ¬æ¬Ö¬Ü¬ä¬Ñ¬ç ¬Ý¬Ö¬Ü¬Ñ¬â¬ã¬ä¬Ó¬à ¬Ó¬â¬Ö¬Þ¬Ö¬ß¬ß¬à ¬à¬ä¬Þ¬Ö¬ß¬ñ¬Ö¬ä¬ã¬ñ.
¬°¬Õ¬ß¬Ñ¬Ü¬à ¬ß¬Ñ ¬ã¬â¬Ö¬Õ¬ã¬ä¬Ó¬à ¬¬¬ã¬Ñ¬Ý¬Ü¬à¬â¬Ú (Crizotinib) - Xalkori (¬¬¬â¬Ú¬Ù¬à¬ä¬Ú¬ß¬Ú¬Ò) ¬à¬ä¬Ù¬í¬Ó¬í
¬Ó¬ã¬ä¬â¬Ö¬é¬Ñ¬ð¬ä¬ã¬ñ ¬Ý¬Ú¬ê¬î ¬á¬à¬Ý¬à¬Ø¬Ú¬ä¬Ö¬Ý¬î¬ß¬í¬Ö. ¬±¬â¬Ö¬á¬Ñ¬â¬Ñ¬ä ¬ç¬à¬â¬à¬ê¬à ¬á¬Ö¬â¬Ö¬ß¬à¬ã¬Ú¬ä¬ã¬ñ ¬à¬â¬Ô¬Ñ¬ß¬Ú¬Ù¬Þ¬à¬Þ.

¬±¬à¬Ò¬à¬é¬ß¬í¬Ö ¬â¬Ö¬Ñ¬Ü¬è¬Ú¬Ú
¬Ô¬à¬Ý¬à¬Ó¬à¬Ü¬â¬å¬Ø¬Ö¬ß¬Ú¬ñ; ¬ß¬Ö¬Û¬â¬à¬á¬Ñ¬ä¬Ú¬ñ; ¬á¬à¬ß¬Ú¬Ø¬Ö¬ß¬Ú¬Ö ¬Ñ¬á¬á¬Ö¬ä¬Ú¬ä¬Ñ; ¬ä¬à¬ê¬ß¬à¬ä¬Ñ; ¬Õ¬Ú¬Ñ¬â¬Ö¬ñ; ¬Ù¬Ñ¬á¬à¬â;
¬ß¬Ñ¬â¬å¬ê¬Ö¬ß¬Ú¬ñ ¬Ù¬â¬Ö¬ß¬Ú¬ñ.

¬¤¬Õ¬Ö ¬Ü¬å¬á¬Ú¬ä¬î ¬Ý¬Ö¬Ü¬Ñ¬â¬ã¬ä¬Ó¬à
¬µ ¬ß¬Ñ¬ã ¬ß¬Ñ ¬ã¬Ñ¬Û¬ä¬Ö ¬Ü¬Ñ¬Ø¬Õ¬í¬Û ¬á¬à¬Ü¬å¬á¬Ñ¬ä¬Ö¬Ý¬î ¬Þ¬à¬Ø¬Ö¬ä ¬Ü¬å¬á¬Ú¬ä¬î ¬Ý¬Ö¬Ü¬Ñ¬â¬ã¬ä¬Ó¬à ¬á¬à ¬á¬â¬Ú¬Ö¬Þ¬Ý¬Ö¬Þ¬à¬Û ¬ã¬ä¬à¬Ú¬Þ¬à¬ã¬ä¬Ú.
¬¯¬Ñ ¬Þ¬Ö¬Õ¬Ú¬Ü¬Ñ¬Þ¬Ö¬ß¬ä ¬¬¬ã¬Ñ¬Ý¬Ü¬à¬â¬Ú (Crizotinib) - Xalkori (¬¬¬â¬Ú¬Ù¬à¬ä¬Ú¬ß¬Ú¬Ò) ¬è¬Ö¬ß¬Ñ ¬Õ¬à¬ã¬ä¬å¬á¬ß¬Ñ ¬Ü¬Ñ¬Ø¬Õ¬à¬Þ¬å
¬á¬à¬Ü¬å¬á¬Ñ¬ä¬Ö¬Ý¬ð. ¬£¬í ¬Þ¬à¬Ø¬Ö¬ä¬Ö ¬Ù¬Ñ¬Ü¬Ñ¬Ù¬Ñ¬ä¬î ¬Õ¬à¬ã¬ä¬Ñ¬Ó¬Ü¬å ¬Þ¬Ö¬Õ¬Ú¬Ü¬Ñ¬Þ¬Ö¬ß¬ä¬Ñ ¬á¬à ¬å¬Ü¬Ñ¬Ù¬Ñ¬ß¬ß¬à¬Þ¬å ¬ß¬à¬Þ¬Ö¬â¬å ¬ä¬Ö¬Ý¬Ö¬æ¬à¬ß¬Ñ ¬Ý¬Ú¬Ò¬à
¬à¬æ¬à¬â¬Þ¬Ú¬ä¬î ¬á¬à¬Ü¬å¬á¬Ü¬å ¬á¬â¬ñ¬Þ¬à ¬Ó ¬æ¬à¬â¬Þ¬Ö ¬Ù¬Ñ¬Ü¬Ñ¬Ù¬Ñ. ¬¦¬ã¬Ý¬Ú ¬Ó¬Ñ¬Þ ¬ä¬â¬Ö¬Ò¬å¬Ö¬ä¬ã¬ñ ¬Ý¬Ö¬Ü¬Ñ¬â¬ã¬ä¬Ó¬à
¬¬¬ã¬Ñ¬Ý¬Ü¬à¬â¬Ú (Crizotinib) - Xalkori (¬¬¬â¬Ú¬Ù¬à¬ä¬Ú¬ß¬Ú¬Ò) ¬ã¬ä¬à¬Ú¬Þ¬à¬ã¬ä¬î ¬Ó ¬ß¬Ñ¬ê¬Ö¬Û ¬Ú¬ß¬ä¬Ö¬â¬ß¬Ö¬ä ¬Ñ¬á¬ä¬Ö¬Ü¬Ö
¬ß¬Ñ¬Þ¬ß¬à¬Ô¬à ¬ß¬Ú¬Ø¬Ö, ¬é¬Ö¬Þ ¬Ó ¬Õ¬â¬å¬Ô¬Ú¬ç ¬á¬å¬ß¬Ü¬ä¬Ñ¬ç ¬á¬â¬à¬Õ¬Ñ¬Ø¬Ú. ¬±¬â¬Ú¬à¬Ò¬â¬Ö¬ä¬Ö¬ß¬Ú¬Ö ¬Þ¬Ö¬Õ¬Ú¬Ü¬Ñ¬Þ¬Ö¬ß¬ä¬Ñ ¬ß¬Ñ ¬ß¬Ñ¬ê¬Ö¬Þ
¬ã¬Ñ¬Û¬ä¬Ö ¬Ô¬Ñ¬â¬Ñ¬ß¬ä¬Ú¬â¬å¬Ö¬ä ¬Ó¬Ñ¬Þ ¬Ó¬í¬ã¬à¬Ü¬à¬Ö ¬Ü¬Ñ¬é¬Ö¬ã¬ä¬Ó¬à ¬ß¬å¬Ø¬ß¬à¬Ô¬à ¬Ý¬Ö¬Ü¬Ñ¬â¬ã¬ä¬Ó¬Ñ ¬Ú ¬ï¬Ü¬à¬ß¬à¬Þ¬Ú¬ð ¬Õ¬Ö¬ß¬Ö¬Ô.
¬£¬í ¬Þ¬à¬Ø¬Ö¬ä¬Ö ¬Ù¬Ñ¬Ü¬Ñ¬Ù¬Ñ¬ä¬î ¬ß¬Ö¬à¬Ò¬ç¬à¬Õ¬Ú¬Þ¬à¬Ö ¬Ý¬Ö¬Ü¬Ñ¬â¬ã¬ä¬Ó¬à, ¬ß¬Ö ¬Ó¬í¬ç¬à¬Õ¬ñ ¬Ú¬Ù ¬Õ¬à¬Þ¬Ñ, ¬á¬â¬ñ¬Þ¬à ¬ã¬Ö¬Û¬é¬Ñ¬ã!



Crizocent ¬ã¬ä¬à¬Ú¬Þ¬à¬ã¬ä¬î